Osimertinib (TAGRISSO)

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor

Osimertinib (TAGRISSO)

Forms and strengths
Form: TabletStrength: 40 mg, 80 mg
Print

Indication

  • Osimertinib is used as adjuvant therapy after tumour removal in patients with early-stage (IB-IIIA) non-small cell lung cancer (NSCLC) whose tumours have EGFR exon 19 deletion or exon 21 (L858R) mutations.
  • Osimertinib is used to treat locally advanced, unresectable (stage III) EGFR mutation-positive NSCLC that has not progressed after platinum-based chemoradiation therapy.
  • Osimertinib is used as first-line treatment, alone or combined with pemetrexed and platinum-based chemotherapy, for locally advanced or metastatic EGFR mutation-positive NSCLC.
  • Osimertinib is used to treat locally advanced or metastatic NSCLC with the EGFR T790M mutation that has progressed after previous EGFR tyrosine kinase inhibitor therapy.
  • A validated laboratory test confirming EGFR mutation status is required before starting osimertinib for any indication.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.